Liminatus Pharma, Inc. Class A Common Stock
NASDAQ: LIMN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Chris Kim
- Employees
- 3
- Headquarters
- La Palma, United States
- IPO year
- 2025
- Market cap
- $2.8M
- Website
- https://liminatuspharma.com
Loading LIMN…
Loading profile data…Frequently asked questions about LIMN
What does Liminatus Pharma, Inc. Class A Common Stock (LIMN) do?
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Where does LIMN trade?
Liminatus Pharma, Inc. Class A Common Stock (LIMN) trades on the NASDAQ Global Select.
What sector is LIMN in?
Liminatus Pharma, Inc. Class A Common Stock (LIMN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Liminatus Pharma, Inc. Class A Common Stock?
Chris Kim is the chief executive officer of Liminatus Pharma, Inc. Class A Common Stock (LIMN).
Where is Liminatus Pharma, Inc. Class A Common Stock headquartered?
Liminatus Pharma, Inc. Class A Common Stock is headquartered in United States.
Does LIMN pay a dividend?
Liminatus Pharma, Inc. Class A Common Stock (LIMN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LIMN go public?
Liminatus Pharma, Inc. Class A Common Stock (LIMN) completed its initial public offering in 2025.